Business Wire

GlobalLogic OTT Service Offerings for Streaming Platforms Proven to Significantly Reduce Go-to-Market Timelines

7.12.2021 16:00:00 EET | Business Wire | Press release

Share

GlobalLogic Inc., a Hitachi Group Company and leader in Digital Engineering, today announced availability of technology accelerators that significantly reduce time to market of custom Over-The-Top (OTT) applications by as much as 30 to 50 percent. This is accomplished through the development of advanced solution accelerators for application development and testing across all major mainstream OTT platforms. GlobalLogic delivers this capability through a software engineering team with deep expertise in the end-to-end OTT value chain, which has developed more than 200 complex applications over the past ten years as part of multiple global OTT services rollouts.

OTT Digital Accelerators

The world of streaming applications has become immense and complex. Consumers demand high-quality, immersive viewing experiences from any provider on any device. To satisfy this demand and increase consumer engagement, OTT service providers must develop extremely efficient, native application experiences across multiple platforms, including living room (Smart TV, Streaming Device), mobile, web and gaming environments. Streaming applications must be highly reliable and resilient, to assure content will be available 24/7. And systems must be robust to enable providers to monetize the service. Global rollouts add additional complexity to the entire development process.

Over the last ten years, GlobalLogic has been delivering custom OTT platform application development services for more than 20 streaming platform customers—resulting in the creation of best practice frameworks and accelerators for faster development of OTT services. The GlobalLogic OTT Channel Development Accelerator and TestLab are two such accelerators enabling GlobalLogic customers such as media companies to create exceptionally reliable, immersive experiences for consumers.

The accelerators are platform-agnostic—compatible with the most commonly used consumer streaming services—as well as device-agnostic, supporting gaming consoles, set-top boxes, smartphones, PCs, and tablets. They also support management of multiple devices from a single interface.

OTT Channel Development Accelerator : A customizable media platform that enables the creation of a fully functional, completely branded OTT channel or app from idea to launch-ready in just 2.5 months.1

Key Features and Benefits:

  • Common code base for native applications on similar platforms
  • Support for all VOD models (AVOD, SVOD, TVOD)
  • Advanced, customizable UI/UX features such as unlimited screens or background video
  • Versatile monetization options such as in-app purchases, subscription billing, or ad-based services
  • Code base owned by client with flexible GlobalLogic engagement models

OTT TestLab Accelerator : A unified infrastructure that schedules automated quality assurance tests on all OTT devices. Clients can test on their own devices, or leverage GlobalLogic’s devices and labs. This is further enhanced by custom, automated test cases for all major platforms and use cases.

Key Features and Benefits:

  • Makes testing possible as soon as channel development project begins
  • Jump starts continuous integration/continuous delivery (CI/CD) pipelines
  • Simple KPI set up and viewing with easy app adjustment capabilities based on results
  • Eliminates need to purchase duplicate equipment dedicated to each device
  • 3,000+ test devices spanning all major platforms, vendors, use-cases

“The OTT application landscape has grown dramatically larger and more complex over the past few years, and our clients are seeking partners to help navigate it,” said Arun Mukunda, VP and Global Head, Media and Entertainment, GlobalLogic. “Having delivered hundreds of complex OTT applications, GlobalLogic is in a unique position to help our clients rapidly create and launch high quality streaming services on a global scale at a pace never before possible.”

About GlobalLogic

GlobalLogic (www.globallogic.com) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.

GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.


1 Approximate time frame based on building and launching a standard app. More complex apps may take longer.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

GlobalLogic, Inc. (Global)
Heather Ailara
211 Communications
+1.973.567.6040
heather@211comms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye